AZN Astrazeneca PLC

44.34
+0.16  (+0%)
Previous Close 44.18
Open 44.36
Price To Book 8.59
Market Cap 116,337,193,476
Shares 2,623,752,672
Volume 1,500,185
Short Ratio 4.36
Av. Daily Volume 2,929,825

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 preliminary data due 3Q 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2020.
Tezepelumab - NAVIGATOR
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
NDA filing due October 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020+.
Farxiga (Dapa-CKD)
Chronic Kidney Disease
Phase 3 data presented 18 March, 2019 noted 18% decrease in MACE events vs placebo.
Farxiga - DECLARE
Type-2 diabetes
Phase 1 trial - two patients have recorded complete responses.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data released November 1, 2017 - primary endpoint not met.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 data due 2H 2019.
Farxiga (Dapa-HF)
Heart failure
Phase 3 data released May 30, 2018. Primary endpoint not met.
Benralizumab - TERRANOVA
COPD
Phase 3 data due 2H 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020+.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data due 2H 2019.
Breztri - (ETHOS)
Chronic obstructive pulmonary disease (COPD)
FDA approval announced September 13, 2018.
Moxetumomab
Cancer - leukaemia
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data 2H 2019.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data released December 7, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data released April 24, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (ARCTIC)
Non-small cell lung cancer (NSCLC)
Approval announced February 19, 2018.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data released February 25, 2019 met primary endpoint.
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data are due 2H 2019.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Approval announced October 31, 2017.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017. Approval announced May 18, 2018.
Lokelma (ZS-9)
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Approval announced November 14, 2017.
Benralizumab
Severe, uncontrolled asthma
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data met primary and secondary endpoints. ORR; 72.2% vs 51.4% for chemotherapy. PFS 13.4 months vs 9.2 months for chemo arm (HR 0.62).
Lynparza - SOLO 3
Third-line ovarian cancer
Phase 3 data at ASCO noted median PFS 7.4 months vs 3.8 months for placebo. HR 0.53.
Lynparza (POLO)
Pancreatic cancer
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (POSEIDON)
Non-small cell lung cancer (NSCLC)
Phase 3 interim analysis noted primary endpoint met - June 27, 2019. Data to be presented 2H 2019.
Imfinzi + tremelimumab (CASPIAN)
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
Phase 3 trial did not meet primary endpoint - noted May 11, 2018.
Fasenra (benralizumab) - GALATHEA
Chronic obstructive pulmonary disease (COPD)
Phase 3 trial met primary endpoint - August 7, 2019.
Lynparza
Castration-Resistant Prostate Cancer
Phase 3 data June 6, 2019 met primary endpoint. Presentation of data 2H 2019.
Calquence
1st line - Chronic lymphocytic leukaemia
Phase 3 data met primary endpoint - August 14, 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 1b/2 data likely due 2019.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 final OS data released August 9, 2019. Endpoint met.
Tagrisso - FLAURA
Non-small cell lung cancer (NSCLC)
Phase 3 data due 1H 2020.
Brilinta (THALES)
Acute ischaemic stroke
Phase 3 data due 2H 2020.
Epanova
Hypertriglyceridaemia CVOT
Phase 3 data due 2020.
Fasenra
Nasal polyps
Phase 3 data due 2H 2020.
Imfinzi
Neoadjuvant Non-small cell lung cancer (NSCLC)
Phase 2 trial met primary endpoint - noted April 4, 2019.
Fasenra
Hypereosinophilic Syndrome
Phase 3 data due 2020+.
Trastuzumab deruxtecan - DESTINY-Breast04
HER low breast cancer
Phase 3 data due 2020+.
Trastuzumab deruxtecan - DESTINY-Breast03
Second line HER2+ breast cancer
Phase 3 data due 2020+.
Trastuzumab deruxtecan DESTINY-Breast02
Third line HER2+ breast cancer
Phase 2 data met primary endpoint - May 8, 2019. BLA filing due 2H 2019.
Trastuzumab deruxtecan - - DESTINY-Breast01
Third line HER2+ breast cancer
Phase 3 data due 2020+.
Fasenra
Asthma
Phase 3 data due 2020+.
Farxiga (Deliver)
Chronic Heart Failure (CHF), preserved ejection fraction (HFpEF)
Phase 3 positive interim data released May 7, 2019. Trial to be stopped early.
Calquence
Relapsed/refractory chronic lymphocytic leukaemia
FDA approval announced May 3, 2019.
Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)
Type 2 diabetes
CRL issued for sNDA announced July 15, 2019.
Farxiga (Depict)
Type 1 diabetes
Phase 3 data due 2H 2020.
PT027
Asthma
Phase 3 data due 2H 2020.
Imfinzi
Non-small cell lung cancer (NSCLC)
Phase 2 data due 1H 2020.
Trastuzumab deruxtecan - Gastric01
Gastric cancer

Latest News

  1. Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
  2. AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
  3. Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
  4. Agios Rides High on Tibsovo Sales Amid Acute Competition
  5. Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
  6. 3 Healthcare Stocks at All-Time Highs: Are They Buys?
  7. CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
  8. LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
  9. AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
  10. Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
  11. No-deal Brexit could deepen Europe's shortage of medicines - experts
  12. AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
  13. Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
  14. TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer
  15. Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
  16. LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
  17. The CEO Who Capped a $37 Billion Recovery With a Cancer Drug Deal
  18. 3 Lung Cancer Stocks That Could Soar in September
  19. It Might Be Better To Avoid AstraZeneca PLC's (LON:AZN) Upcoming 1.0% Dividend
  20. Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates